Show
Sort by
-
Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up
-
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy
-
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study
-
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity
-
Bone and joint diseases in inflammatory bowel disease
-
The role of gut inflammation in the pathogenesis of spondyloarthropathies
-
Long-term evolution of gut inflammation in patients with spondyloarthropathy
-
Spondylarthropathies: from gut to target organs
-
Course of gut inflammation in spondylarthropathies and therapeutic consequences
-
The evolution of spondyloarthropathies in relation to gut histology, 1: clinical aspects